Drug intelligence / Profile preview

AQB-121

Development stage: Preclinical
Lead developer: Aquavit Pharmaceuticals
Administration: Intradermal

Overview

AQB-121, also called iMicrotox, is an **Aquavit Pharmaceuticals** investigational drug-device combination product designed for intradermal microchannel delivery of botulinum toxin in the periorbital area for aesthetic use. The program uses Aquavit's microchannel technology to enable controlled, fixed-depth placement of botulinum toxin across a broad treatment area. The specific botulinum toxin product, serotype, molecular target, and pharmacodynamic details have not been publicly disclosed.

Other names: iMicrotox

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on AQB-121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AQB-121.

Explore the full profile